AstraZeneca Advances In Early Stage Lung Cancer With Imfinzi And Tagrisso
Pursuing Leaders With Double Neoadjuvant/Adjuvant Approach
AstraZeneca’s Imfinzi is playing catch-up to other PD1/L1 targeting agents in neoadjuvant/adjuvant NSCLC with new data from AEGEAN, but new survival data for Tagrisso from ADAURA consolidate its dominance in early-stage EGFR positive disease.
You may also be interested in...
A positive showing by Bristol Myers Squibb’s checkpoint inhibitor Opdivo in non-small cell lung cancer could broaden its use, though much depends on the magnitude of the hit.
The PD-L1 inhibitor showed efficacy in the neoadjuvant/adjuvant setting, where Merck is developing Keytruda as well. BMS’s Opdivo was the first to win approval in neoadjuvant NSCLC.
Without disclosing data, the company reported positive pathological complete response data from the AEGEAN study of its PD-L1 inhibitor Imfinzi in neoadjuvant NSCLC, where BMS’s Opdivo won approval in March.